We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Factory Location: flat/rm 905 workingberg commercioul bldg,14-47 marble road,HK
invoice:Room 563 ,Newcity Plaza ,Jianggan District ,Hangzhou ,China
Main Sales Markets: Central/South America,Asia,Middle East
Monthly Production Capacity: 10ton
Packaging Information: 25kg/drum
Delivery Lead Time: PROMPT
Sample Provided: yes
Payment Terms: TT/LC/DA
Keywords
buy /sell PSI 7977
PSI 7977 high quality 99%min.
1190307-88-0 in stock
Quick Details
ProName: PSI 7977
CasNo: 1190307-88-0
Appearance: white powder
Application: Antiviral
DeliveryTime: in time
PackAge: aluminum foil bag
Port: Shanghai
ProductionCapacity: Metric Ton/Day
Purity: >98%
Storage: at -20℃
Transportation: by air
LimitNum: 0 Metric Ton
Superiority
PSI-7977 is an investigational nucleotide analog currently in Phase 2 for treatment of chronic HCV infection. PSI-7851 is a mixture of two similar molecules, PSI-7976 and PSI-7977
Details
PSI-7977 is an investigational nucleotide analog currently in Phase 2 ftreatment ofonic HCV infection. PSI-7851 is a mixture of two similar molecules, PSI-7976 PSI-7977, which exist in PSI-7851 as isomers of each other. Once inside a liver cell, both molecules are rapidly converted to the same active triphosphate. Given the ability to more easily manufacture PSI-7977, potentially advantageous in vitroacteristics, PSI-7977 wased ffurther clinical development.
Three years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
